This webinar reviews the validation and clinical implementation of BRCAplus, a multi-gene hereditary breast cancer test. Although BRCA1 and BRCA2 account for a large portion of hereditary breast cancer, there are many other genes that differentially impact the risk for breast cancer. BRCAplus was designed to test for mutations in genes that are known to have a high breast cancer risk and that have management guidelines associated with them. With the advent of next-generation sequencing (NGS), it is now possible to test for multiple genes that can increase the risk to develop breast cancer at once.